ClinicalTrials.gg
CompletedNCT06077864Updated Nov 12, 2026

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

A Phase 3 interventional study of survodutide and Placebo in Obesity, sponsored by Boehringer Ingelheim. Completed at 543 sites in 35 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Enrollment updated5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Enrollment
Largest of 22
5,530 · median 121
Started
2023
with 3 others
Phase 3
9 of 22
3 open now
Registered
6th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one has the largest enrollment, is one of 4 that started in 2023, is one of 9 in phase 3, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet.

The purpose of this study is to find out whether people with overweight or obesity who take a medicine called survodutide (BI 456906) are less or more likely to develop serious cardiovascular problems. It also aims to find out whether health parameters like blood pressure improve. Overweight and obesity are linked to cardiovascular disease. Survodutide is a medicine that is developed to help people with obesity or overweight to lose weight.

Participants are divided into 3 groups of almost equal size. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under the skin once a week. All participants also receive counselling on diet and physical activity.

Participants are in the study for up to 2 years and 3 months. During this time, it is planned that participants visit the study site up to 21 times and attend remote visits by video calls. During these visits, the doctors check participants' cardiovascular and overall health. The results are compared between survodutide and placebo groups. The study staff also takes note of any unwanted effects.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years at the time of signing , and at least the legal age of consent in countries where it is >18 years.
  2. (BMI) ≥27 kg/m2 at screening with established cardiovascular disease (CVD) and/or at least 2 weight-related complications or risk factors for CVD OR BMI ≥30 kg/m2 at screening with established CVD or chronic kidney disease (CKD), and/or at least 2 weight-related complications or risk factors for CVD.

Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Previous treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists within 3 months before screening.
  2. Type 1 diabetes.
  3. Less than 3 months between the last dose of GLP-1R agonists and GLP-1R agonist/insulin/glucose-dependent insulinotropic polypeptide (GIP) combinations and screening.
  4. Known gastric emptying abnormality (e.g., severe diabetic gastroparesis or gastric outlet obstruction).

Further exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,530 participants (actual)

Study arms

  • Experimental
    survodutide 3.6 mg

    Combination Product: survodutide

  • Experimental
    survodutide 6.0 mg

    Combination Product: survodutide

  • Placebo comparator
    Placebo

    Combination Product: Placebo

Interventions

  • Combination productsurvodutide

    once weekly subcutaneous injection, pre-filled syringe

    Also known as: BI 456906

  • Combination productPlacebo

    once weekly subcutaneous injection, pre-filled syringe

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate non-inferiority)

    Heart failure events (HFE) includes hospitalisation for heart failure (HHF), emergency room visit, urgent care visit, or urgent outpatient heart failure (HF) visit (5-point major adverse cardiac event (5P-MACE)) CV-Cardiovascular MI-Myocardial infarction

    Time frame: up to Week 114

Secondary outcomes

  1. Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, or non-fatal MI (3-point major adverse cardiac event (3P-MACE)) (to demonstrate non-inferiority)

    Time frame: up to Week 114

  2. Absolute change in systolic blood pressure (SBP) (mmHg) from baseline to Week 72

    Time frame: Baseline and at Week 72

  3. Absolute change in waist circumference (cm) from baseline to Week 72

    Time frame: Baseline and at Week 72

  4. Absolute change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) from baseline to Week 72 in trial participants with HF at baseline

    KCCQ-TSCC scale score range is from 0 to 100 where low score means patient not doing well and higher score means patient doing better.

    Time frame: At Baseline and at Week 72

  5. Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate superiority)

    Time frame: up to Week 114

  6. Percentage change in body weight from baseline to Week 72

    Time frame: Baseline and at Week 72

  7. Absolute change in diastolic blood pressure (DBP) (mmHg) from baseline to Week 72

    Time frame: Baseline and at Week 72

  8. Absolute change in aspartate aminotransferase (AST) (U/L) from baseline to Week 72

    Time frame: Baseline and at Week 72

  9. Absolute change in alanine aminotransferase (ALT) (U/L) from baseline to Week 72

    Time frame: Baseline and at Week 72

  10. Absolute change in glycosylated haemoglobin A1c (HbA1c) (mmol/mol) from baseline to Week 72 in trial participants with type 2 diabetes mellitus (T2DM)

    Time frame: Baseline and at Week 72

  11. Absolute change in HbA1c (%) from baseline to Week 72 in trial participants with T2DM

    Time frame: Baseline and at Week 72

  12. Time to onset of T2DM in trial participants without T2DM at baseline

    Time frame: up to Week 114

  13. Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, or ischaemia related coronary revascularisation (4-point major adverse cardiac event (4P-MACE))

    Time frame: up to Week 114

  14. Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, or HFE (3P-MACE+ HFE)

    Time frame: up to Week 114

  15. Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, or non-fatal MI (3P-MACE)

    Time frame: up to Week 114

  16. Time to first occurrence of adjudicated CV death or adjudicated HFE

    Time frame: up to Week 114

  17. Time to first occurrence of adjudicated CV death or adjudicated HHF

    Time frame: up to Week 114

  18. Time to first occurrence of adjudicated HFE

    Time frame: up to Week 114

  19. Time to adjudicated CV death

    Time frame: up to Week 114

  20. Time to all-cause mortality

    Time frame: up to Week 114

  21. Time to first occurrence of adjudicated non-fatal MI

    Time frame: up to Week 114

  22. Time to first occurrence of adjudicated non-fatal stroke

    Time frame: up to Week 114

  23. Time to first occurrence of adjudicated ischaemia related coronary revascularisation

    Time frame: up to Week 114

  24. Achievement of body weight reduction ≥5% from baseline to Week 72

    Time frame: Baseline and at Week 72

  25. Achievement of body weight reduction ≥10% from baseline to Week 72

    Time frame: Baseline and at Week 72

  26. Achievement of body weight reduction ≥15% from baseline to Week 72

    Time frame: Baseline and at Week 72

  27. A composite of death, number of adjudicated HFEs, time to first adjudicated HFE and change from baseline in KCCQ-TSS at 72 weeks assessed by the win ratio in trial participants with HF at baseline

    Win ratio will be assessed as below: The primary efficacy endpoint will be analyzed using the clinical benefit approach comparing every participant in the BI 456906 arm to every participant in the placebo arm to determine a winner. A winner in the pair-wise comparison has a delayed time to the occurrence of death; if that cannot be determined, a winner has fewer HFEs; if the number of HFEs is the same a winner has a delayed time to the occurrence of first HFE; if that rule does not determine a winner, a winner has a more favorable (less increase or more decrease) change in KCCQ-CSS between baseline and at 72 weeks, otherwise the pair will be recorded as tied. The estimated net benefit (win ratio is then calculated as the total number of wins in the BI 456906 group across all strata divided by the total number of losses) will be provided. KCCQ-TSCC scale score range is from 0 to 100 where low score means patient not doing well and higher score means patient doing better.

    Time frame: At baseline and at 72 Weeks

07

Study locations

543 sites
  • Cardiology P.C.
    Birmingham, Alabama 35211, United States
  • AMR Daphne
    Daphne, Alabama 36526, United States
  • AMR Mobile
    Mobile, Alabama 36608, United States
  • Mobile Heart Specialists, PC
    Mobile, Alabama 36608, United States
  • The Institute for Liver Health II DBA Arizona Clinical Trials
    Chandler, Arizona 85225, United States
  • Clinical Research Institute of Arizona, LLC
    Sun City West, Arizona 85375, United States
  • AMR Phoenix
    Tempe, Arizona 85281, United States
  • Arizona Liver Health-Tucson-67516
    Tucson, Arizona 85712, United States
  • Yuma Clinical Trials
    Yuma, Arizona 85364, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Velocity Clinical Research-Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, San Diego
    La Mesa, California 91942, United States
  • Velocity Clinical Research - Los Angeles
    Los Angeles, California 90017, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
  • Velocity Clinical Research, Santa Ana
    Santa Ana, California 92704, United States
  • NorthBay Clinical Research, LLC
    Santa Rosa, California 95405, United States
  • Velocity Clinical Research-Van Nuys-70286
    Van Nuys, California 91405, United States
  • Peak Gastroenterology Associates-Colorado Springs-62256
    Colorado Springs, Colorado 80907, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Proactive Clinical Research
    Boca Raton, Florida 33431, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Nature Coast Clinical Research-Crystal River-62355
    Crystal River, Florida 34429, United States
  • Beautiful Minds Clinical Research Center
    Cutler Bay, Florida 33157, United States
  • AMR Fort Myers
    Fort Myers, Florida 33912, United States
  • Covenant Metabolic Specialists, LLC - Fort Myers
    Fort Myers, Florida 33912, United States
  • Velocity Clinical Research-Hallandale Beach-67888
    Hallandale, Florida 33009, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Clinical Site Partners LLC
    Leesburg, Florida 34748, United States
  • Flourish Research - Miami
    Miami, Florida 33135, United States
  • Verus Clinical Research Corporation
    Miami, Florida 33135, United States
  • Center for Diabetes, Obesity and Metabolism
    Pembroke Pines, Florida 33024, United States
  • Synexus-Pinellas Park-69294
    Pinellas Park, Florida 33781, United States
  • East Coast Institute for Research, LLC-Saint Augustine-63032
    Saint Augustine, Florida 32086, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172, United States
  • Santos Research Center, Corp.
    Tampa, Florida 33615, United States
  • Covenant Metabolic Specialists, LLC - Sarasota
    University Park, Florida 34201, United States
  • Javara-Albany-67356
    Albany, Georgia 31707, United States
  • Centricity Research Columbus Georgia Multispecialty
    Columbus, Georgia 31904, United States
  • Javara-Fayetteville-67354
    Fayetteville, Georgia 30214, United States
  • NSC Research Inc
    Johns Creek, Georgia 30024, United States
  • The Jones Center Clinical Research, LLC
    Macon, Georgia 31210, United States
  • Urban Family Practice Associates, PC
    Marietta, Georgia 30067, United States
  • Javara-Savannah-67450
    Savannah, Georgia 31406, United States
  • Endeavor Health Clinical Operations - Northwest Community Healthcare
    Arlington Heights, Illinois 60005, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • Medisphere Medical Research Center
    Evansville, Indiana 47714, United States
  • McFarland Clinic PC
    Ames, Iowa 50010, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
  • AMR El Dorado
    El Dorado, Kansas 67042, United States
  • AMR Newton
    Newton, Kansas 67114, United States
  • AMR Clinical Wichita
    Wichita, Kansas 67226, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Grace Research, LLC-Bossier City-51040
    Bossier City, Louisiana 71111, United States
  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • AMR New Orleans
    New Orleans, Louisiana 70119, United States
  • Grace Research, LLC-Shreveport-64616
    Shreveport, Louisiana 71105, United States
  • Javara Inc.-Annapolis-68997
    Annapolis, Maryland 21401, United States
  • Ascension Saint Agnes Heart Care
    Baltimore, Maryland 21229, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Domino's Farms
    Ann Arbor, Michigan 48105, United States
  • Elite Research Center, LLC
    Flint, Michigan 48532, United States
  • Healthy Heart Cardiology
    Grand Rapids, Michigan 49546, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • The National Diabetes & Obesity Research Institute
    Diamondhead, Mississippi 39525, United States
  • Prime Health and Wellness
    Fayette, Mississippi 39069, United States
  • Velocity Clinical Research-Gulfport-68930
    Gulfport, Mississippi 39503, United States
  • Johnson County ClinTrials
    Kansas City, Missouri 64112, United States
  • AMR Kansas City
    Kansas City, Missouri 64114, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Sundance Clinical Research, LLC
    St Louis, Missouri 63141, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Skyline Medical Center
    Elkhorn, Nebraska 68022, United States
  • Methodist Physicians Clinic
    Fremont, Nebraska 68025, United States
  • AMR Las Vegas
    Las Vegas, Nevada 89119, United States
  • Advanced Heart Care, LLC
    Bridgewater, New Jersey 08807, United States
  • NJ Heart LLC
    Linden, New Jersey 07036, United States
  • IMA Clinical Research-Warren-69742
    Warren Township, New Jersey 07059, United States
  • IMA Clinical Research Albuquerque
    Albuquerque, New Mexico 87109, United States
  • Velocity Clinical Research - Binghamton
    Binghamton, New York 13905, United States
  • Synexus Clinical Research US, Inc.
    New York, New York 10017, United States
  • Saratoga Clinical Research, LLC
    Saratoga Springs, New York 12866, United States
  • Accellacare of Cary
    Cary, North Carolina 27518, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Javara-Charlotte-67884
    Charlotte, North Carolina 28210, United States
  • Accellacare-Mooresville-69123
    Mooresville, North Carolina 28117, United States
  • Centricity Research (New Bern)
    New Bern, North Carolina 28562, United States
  • Wake Forest University Health Sciences-Winston-Salem-69719
    Winston-Salem, North Carolina 27104, United States
  • Velocity Clinical Research-Cincinnati-69044
    Cincinnati, Ohio 45242, United States
  • Synexus Clinical Research-Columbus-69427
    Columbus, Ohio 43212, United States
  • Centricity Research-Columbus-68879
    Columbus, Ohio 43213, United States
  • Aventiv Research Inc.-Dublin-62009
    Dublin, Ohio 43016, United States

Showing the first 100 of 543 sites across 35 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bozkurt B, le Roux CW, Wharton S, Butt JH, Startseva E, Sumin M, Marshall SR, Hussain SA, Schnaidt S, Petrie MC, Pocock SJ, Gregson J, Ard JD, Bogdanski P, Cercato C, Farias JM, Goudev A, Hjelmesaeth J, Kaul U, Kokkinos AD, Lin WY, Matoulek M, Merkely B, Silva-Nunes J, Ogawa W, Pedersen SD, Pietilainen KH, Sattar N, Reyna LS, Schou M, Seufert J, Sharman A, Sourij H, Tinahones FJ, van Beek AP, Vangoitsenhoven R, Yazici D, Younes R, Kaplan LM; SYNCHRONIZE-CVOT investigators. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Nov 9:S0140-6736(26)02140-9. doi: 10.1016/S0140-6736(26)02140-9. Online ahead of print. PubMed 43003106 ↗
  • Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, Unseld A, Startseva E, Kaplan LM; SYNCHRONIZE-CVOT Trial Committees and Investigators. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. 2024 Dec;12(12):2101-2109. doi: 10.1016/j.jchf.2024.09.004. Epub 2024 Oct 23. PubMed 39453356 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2026, 30 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 30 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 11, 2023
StartActual
Nov 20, 2023
Primary completionActual
Jun 1, 2026
CompletionActual
Jun 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 2 sites removed
Show 5 added (1 Australia, 1 Brazil, 1 South Korea, 1 Taiwan, 1 United Kingdom)
  • The Boden Initiative · The University of Sydney, Australia
  • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • Yonsei University Wonju Severance Christian Hospital · Wonju-si, Gangwon State, South Korea
  • China Medical University Hospital · Taichung, Taiwan
  • Synexus - Midlands · Birmingham, United Kingdom
Show 2 removed
  • The Boden Initiative · Camperdown, Australia
  • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
across 3 updates, Sep 30, 2026 – Nov 12, 2026
Enrollment
5531→5530
Oct 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 43003106 ↗
Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 43003106 ↗
    1 site added
    Show site
    • Synexus - Midlands · Birmingham, United Kingdom
    + 1 other change: verification date
  2. Oct 29, 2026
    3 sites added, 1 site removed
    Show 3 added (1 Brazil, 1 South Korea, 1 Taiwan)
    • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
    • Yonsei University Wonju Severance Christian Hospital · Wonju-si, Gangwon State, South Korea
    • China Medical University Hospital · Taichung, Taiwan
    Show 1 removed
    • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
    Enrollment 5531→5530
    + 1 other change: verification date
  3. Sep 30, 2026
    1 site added, 1 site removed
    Show site
    • The Boden Initiative · The University of Sydney, Australia
    Show 1 removed
    • The Boden Initiative · Camperdown, Australia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06077864
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Nov 20, 2023
Primary completion
Jun 1, 2026
Completion
Jun 30, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion